Homepage Top Section2

Yale University has developed the intellectual property behind Anteros and was first in-licenced by BMS and later authorised to Anteros. BioMotiv CEO Dr Satish Jindal said: “Anteros Pharmaceuticals

Established in 2011, MaSTherCell Global is a technology-focused cell and gene therapy contract development and manufacturing organisation (CDMO) that serves cell therapy innovators. Catalent chair and CEO John

Under the deal, GSK will provide its pandemic vaccine adjuvant technology to enhance the development of an effective vaccine against 2019-nCoV virus. Coronaviruses are a family of viruses

The APR-246, azacitidine combination has been granted breakthrough therapy status for the treatment of myelodysplastic syndromes in patients having a susceptible TP53 mutation. Myelodysplastic syndromes are defined as

Achillion is mainly focused on the advancement of its oral small molecule complement inhibitors into late-stage development and commercialisation. The deal adds Alexion’s product portfolio with two clinical-stage

Under the deal, Atnahs will purchase global commercial rights related to AstraZeneca’s Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose

The phase III IMvigor010 study assessing Tecentriq as an adjuvant (after surgery) monotherapy treatment has not achieved its primary endpoint of disease-free survival (DFS) compared against observation in

Tazverik, a methyltransferase inhibitor, has been approved to treat adults and paediatric patients aged between 16 years and older with metastatic or locally advanced epithelioid sarcoma sarcoma not

The patient had travelled from Wuhan to Washington. The novel coronavirus infection is believed to have originated at a seafood wholesale market in the Chinese city in Hubei